Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia

• Published in: Alzheimer's & dementia : translational research & clinical interventions Vol. 4; no. 1; pp. 652 - 660
• Main Authors: Willis, Brian A., Sundell, Karen, Lachno, D. Richard, Ferguson-Sells, Lisa R., Case, Michael G., Holdridge, Karen, DeMattos, Ronald B., Raskin, Joel, Siemers, Eric R., Dean, Robert A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 2018; Elsevier
• Subjects: Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Pharmacodynamics; Solanezumab; Solanezumab; Biomarkers; Pharmacodynamics; Cerebrospinal fluid; Alzheimer's disease

Solanezumab treatment was previously shown to significantly increase total (bound + unbound) cerebrospinal fluid (CSF) levels of amyloid β (Aβ)1–40 and Aβ1–42 in patients with mild to moderate Alzheimer's disease dementia yet did not produce meaningful cognitive effects. This analysis assessed...